Gilead Sciences Buy or Sell Recommendation

Macroaxis provides Gilead Sciences Inc buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Gilead Sciences positions. The advice algorithm takes into account all of Gilead Sciences Inc available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Gilead Sciences buy-and-hold prospective. Please also check Gilead Sciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus

Investment Horizon


Risk Tolerance

Execute Advice
Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Gilead Sciences Inc is 'Cautious Hold'.
For the selected time horizon Gilead Sciences Inc has a mean deviation of 1.02, standard deviation of 1.33, variance of 1.77, downside variance of 0.5005, semi variance of (0.19) and expected short fall of (1.37)
Macroaxis provides unbiased buy or sell recommendations on Gilead Sciences that should be used to complement current analysts and expert consensus on Gilead Sciences Inc. Our buy, hold, or sell suggestion engine determines the entity potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Gilead Sciences Inc is not overpriced, please check out all Gilead Sciences fundamentals including its Gross Profit, Debt to Equity and the relationship between Price to Book and Cash and Equivalents . Given that Gilead Sciences Inc has Price to Earning of 4.52 times, we strongly advise you confirm Gilead Sciences Inc market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Returns Distribution Density

Mean Return0.51Value At Risk-0.9927
Potential Upside2.912Standard Deviation1.3295
 Return Density 

Gilead Sciences Greeks

Alpha over DOW
= 0.52 
βBeta against DOW=(0.58) 
Overall volatility
= 1.30 
 IrInformation ratio = 0.34 

Gilead Sciences Volatility Alert

Gilead Sciences Inc exhibits relatively low volatility with skewness of 1.38 and kurtosis of 2.41. However, we advice investors to further investigate Gilead Sciences Inc to make sure all market statistics is disseminated and is consistent with investors' estimations about Gilead Sciences upside potential.
 Better Than Average     
 Worse Than Average Compare Gilead Sciences to competition
FundamentalsGilead SciencesPeer Average
Return On Equity72.25 % (15.17) %
Return On Asset20.23 % (15.64) %
Profit Margin43.42 % (5.50) %
Operating Margin58.65 % (10.91) %
Current Valuation6.82 B152.14 B
Shares Outstanding1.31 B1.43 B
Shares Owned by Insiders0.60 % 6.91 %
Shares Owned by Institutions83.40 % 18.37 %
Number of Shares Shorted10.79 M3.24 M
Price to Earning4.52 times40.69 times
Price to Book4.12 times14.44 times
Price to Sales3.17 times17.81 times
Revenue29.1 B9.85 B
Gross Profit26.13 B21.75 B
EBITDA18.24 B1.41 B
Net Income12.64 B517.71 M
Cash and Equivalents14.71 B3.89 B
Cash per Share11.26 times5.17 times
Total Debt26.32 B7.36 B
Debt to Equity125.80 times0.72 times
Current Ratio2.59 times3.30 times
Book Value Per Share15.64 times13.64 times
Cash Flow from Operations15.46 B1.25 B
Short Ratio1.45 times2.09 times
Earnings Per Share9.46 times2.30 times
Price to Earnings To Growth(1.25) times1.22 times
Number of Employees8 K10.67 K
Market Capitalization92.33 B29.78 B
Total Asset1.29 B126.86 B
Retained Earnings18.15 B38.24 B
Working Capital1.08 B3.58 B
Current Asset1.18 B36.8 B
Cautious Hold


Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

   Sale by John Martin of 63584 shares of Gilead Sciences [view details]
Risk Adjusted Performance0.1222
Market Risk Adjusted Performance(0.85)
Mean Deviation1.02
Downside Deviation0.7075
Coefficient Of Variation263.17
Standard Deviation1.33
Information Ratio0.3425
Jensen Alpha0.5181
Total Risk Alpha0.3194
Sortino Ratio0.6436
Treynor Ratio(0.86)
Maximum Drawdown5.23
Value At Risk(0.99)
Potential Upside2.91
Downside Variance0.5005
Semi Variance(0.19)
Expected Short fall(1.37)

Current Valuation

Gilead Sciences Current Valuation Analysis
Gilead Sciences Inc is rated # 3 in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Pharmaceuticals And Biosciences industry is currently estimated at about 286.88 Billion. Gilead Sciences holds roughly 6.82 Billion in current valuation claiming about 2.38% of equities listed under Pharmaceuticals And Biosciences industry.